Cellectis SA (CLLS) AI Stock Analysis

• Market Cap: $340.79M
• Dividend Yield: N/A
• Average Volume (3M): 144.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 158.54%
• EPS Growth: 66.90%
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 72,093,636
• 10 Day Avg. Volume: 164,211
• 30 Day Avg. Volume: 144,584
• PEG Ratio: 0.06
• Price to Book (P/B): 1.24
• Price to Sales (P/S): 3.93
• P/FCF Ratio: 8.35
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 2.88
• Enterprise Value/Gross Profit: 3.29
• Enterprise Value/Ebitda: -35.74
• 1Y Price Target: $6.00
• Price Target Upside: 53.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $5.00 ▲(28.21% Upside)

Cellectis SA's overall stock score is driven by strong technical indicators and positive earnings call sentiment, offset by weak financial performance and valuation. The company's ongoing clinical trials and strategic partnerships are promising, but financial challenges and legal uncertainties weigh on the score.

Positive Factors

Strategic Partnerships

The partnership with AstraZeneca enhances Cellectis' R&D capabilities and market reach, potentially accelerating the development and commercialization of new therapies.

Clinical Trial Progress

Advancing to Phase II trials signifies progress in clinical validation, increasing the potential for regulatory approval and market entry, crucial for long-term growth.

Cash Position

A strong cash position provides financial stability, enabling continued investment in R&D and operational activities without immediate need for external financing.

Negative Factors

Profitability Challenges

Persistent negative profit margins highlight operational inefficiencies, which could hinder long-term financial sustainability and investor confidence.

Revenue Consistency

Inconsistent revenue growth can affect financial planning and stability, potentially impacting the company's ability to fund future projects and expansions.

Servier Arbitration Uncertainty

Legal disputes can create financial and operational uncertainties, potentially diverting resources and focus from core business activities and strategic goals.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

How the Company Makes Money

Cellectis generates revenue primarily through collaborations and partnerships with other pharmaceutical and biotechnology companies. The company enters into licensing agreements and research collaborations that provide upfront payments, milestone payments based on development progress, and royalties on product sales once commercialized. Additionally, Cellectis may receive funding from grants and public institutions for research and development initiatives. Significant partnerships with major pharmaceutical companies can enhance its revenue stream, as these collaborations often involve shared development costs and profit-sharing arrangements.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA shows strong revenue growth and gross margins, but struggles with profitability and cash flow. The balance sheet indicates moderate leverage, but negative returns on equity highlight inefficiencies. Overall, while there are strengths in revenue growth, the financial health is challenged by persistent losses and cash flow issues.

Income Statement

Cellectis SA shows a strong gross profit margin of 92.11% TTM, indicating efficient cost management. However, the company struggles with profitability, as evidenced by a negative net profit margin of -104.80% TTM and negative EBIT and EBITDA margins. Revenue growth is positive at 37.24% TTM, but the company remains unprofitable, which is a concern.

Balance Sheet

The debt-to-equity ratio of 0.98 TTM suggests moderate leverage, which is manageable. However, the return on equity is negative at -49.81% TTM, indicating inefficiencies in generating returns for shareholders. The equity ratio is not provided, but the overall financial stability is moderate with potential risks due to high leverage.

Cash Flow

Cellectis SA's cash flow situation is challenging, with negative operating cash flow and free cash flow TTM. The free cash flow to net income ratio is positive at 1.10, indicating some ability to cover net losses, but the overall cash flow position is weak, with a negative free cash flow growth rate of -10.61% TTM.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	75.27M	41.51M	755.00K	19.17M	30.35M	51.06M
Gross Profit	65.96M	32.32M	-6.66M	10.69M	28.50M	49.11M
EBITDA	-6.07M	-9.46M	-92.64M	-76.38M	-78.42M	-43.34M
Net Income	-35.35M	-36.76M	-101.06M	-106.14M	-114.20M	-81.07M
Balance Sheet
Total Assets	343.05M	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	52.24M	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	37.58M	91.46M	85.06M	75.77M	100.87M	106.68M
Total Liabilities	242.57M	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	100.48M	131.03M	84.69M	117.97M	221.29M	283.80M
Cash Flow
Free Cash Flow	-32.71M	19.52M	-25.82M	-89.89M	-123.12M	-124.68M
Operating Cash Flow	-29.09M	22.10M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	-68.60M	-102.63M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	-9.70M	89.80M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 3.9 is above the 20-day moving average (MA) of 3.72, above the 50-day MA of 3.65, and above the 200-day MA of 2.24, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 69.71 is Neutral, neither overbought nor oversold. The STOCH value of 84.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	58 Neutral	$340.79M	―	-31.07%	―	158.54%	66.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FHTX	49 Neutral	$199.55M	-2.85	―	―	-3.91%	37.89%
ZURA	43 Neutral	$224.31M	-4.55	-47.85%	―	―	-19.69%
RNAC	41 Neutral	$200.48M	-0.15	―	―	―	―
TNYA	36 Underperform	$224.91M	-1.44	-96.44%	―	―	46.68%
VOR	33 Underperform	$152.06M	―	―	―	―	-1072.48%

Cellectis SA Corporate Events

Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA

On November 19, 2025, Cellectis published an article in Nature Communications highlighting a breakthrough in non-viral gene editing. The company introduced circular single-stranded DNA (CssDNA) as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). This innovation significantly enhances the potential of non-viral gene therapy by achieving higher knock-in efficiency and applicability to multiple cell types, marking a pivotal advance in the development of next-generation cell and gene therapies.

Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025

Cellectis S.A. released its unaudited interim financial report for the nine-month period ending September 30, 2025. The report, prepared in accordance with International Accounting Standard 34, highlights the company’s financial position and operational results. The document also includes management’s discussion and analysis of financial conditions and results of operations, providing insights into the company’s strategic direction and market positioning. This release is significant for stakeholders as it offers a comprehensive view of Cellectis’s financial health and potential challenges, such as regulatory developments and market competition, which could impact its future operations.

Cellectis Showcases Promising Clinical Trial Data at ASH 2025

Cellectis announced the acceptance of two abstracts for presentation at the ASH 2025 annual meeting, highlighting significant advancements in their clinical trials. The first abstract presents promising preliminary data for eti-cel (UCART20x22) in treating relapsed/refractory non-Hodgkin lymphoma, showing an 86% overall response rate and a 57% complete response rate. The second abstract discusses the correlation between alemtuzumab exposure and response in patients treated with lasme-cel (UCART22) for acute lymphoblastic leukemia, indicating improved responses without increased toxicities. These developments underscore Cellectis’ potential to enhance treatment outcomes for challenging cancer cases.

Cellectis to Announce Q3 2025 Financial Results on November 7

On October 31, 2025, Cellectis announced that it will release its third-quarter financial results for 2025 on November 7, 2025, after the US market closes. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance during the quarter. Notably, Cellectis will not host a conference call to discuss these results, but its investor relations team is available for inquiries.

Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL

On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data from the Phase 1 BALLI-01 study of lasme-cel (UCART22) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed lasme-cel was generally well-tolerated and demonstrated significant efficacy, with a 68% overall response rate and 83% achieving minimal residual disease-negative status in the target Phase 2 population. The company announced the initiation of the pivotal Phase 2 trial and outlined a registration path for lasme-cel as a bridge to transplant in r/r ALL, with a Biologics License Application submission anticipated in 2028. This development positions lasme-cel as a potential game-changer in the industry, offering a new treatment option for heavily pretreated patients and potentially capturing a significant share of the market.

Cellectis Showcases Pipeline Progress at R&D Day

On October 16, 2025, Cellectis hosted an R&D Day in New York City, where the company presented the full Phase 1 dataset and outlined the pivotal Phase 2 trial design for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This event highlighted the commercial opportunities and strategic advancements in their pipeline, reinforcing Cellectis’ position in the biotechnology industry as a leader in gene-editing therapies. The presentation of the Phase 1 data and the strategy for Phase 2 trials are significant for stakeholders, as they indicate potential market opportunities and the company’s progress in developing effective treatments for cancer.

Cellectis Unveils Promising Gene Therapy Advances at ESGCT Congress

Cellectis announced the presentation of new research findings at the ESGCT Annual Congress in Sevilla, Spain, from October 7-10, 2025. The company highlighted the potential of circular single-stranded DNA (CssDNA) as a non-viral template for gene therapy, demonstrating high gene insertion frequency and better engraftment in HSPCs compared to viral methods. Additionally, Cellectis presented a study on TALE base editors, showing no significant off-target effects, supporting their safe use in therapeutic applications. These advancements could enhance Cellectis’ position in the gene therapy industry and offer new opportunities for stakeholders.